v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Statement of Comprehensive Income [Abstract]        
Net income/(loss) before allocation to noncontrolling interests $ (237) $ 2,928 $ 2,458 $ 5,901
Foreign currency translation adjustments, net (41) 127 882 (430)
Unrealized holding gains/(losses) on derivative financial instruments, net 121 (273) 85 (395)
Reclassification adjustments for (gains)/losses included in net income/(loss) [1] (11) (106) (2) (419)
Other comprehensive income, cash flow hedge, gain (loss), before tax, total 110 (379) 83 (814)
Unrealized holding gains/(losses) on available-for-sale securities, net (57) 166 (19) 135
Reclassification adjustments for (gains)/losses included in net income/(loss) [2] 22 (83) 43 72
Other comprehensive income (loss), available-for-sale securities, before tax, total (36) 82 24 207
Reclassification adjustments related to amortization of prior service costs and other, net (6) (24) (13) (55)
Reclassification adjustments related to curtailments of prior service costs and other, net 0 (11) (4) (44)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax (6) (35) (18) (99)
Other comprehensive income/(loss), before tax 27 (204) 970 (1,136)
Tax provision/(benefit) on other comprehensive income/(loss) 53 (347) 134 (538)
Other comprehensive income/(loss) before allocation to noncontrolling interests (26) 143 837 (598)
Comprehensive income/(loss) before allocation to noncontrolling interests (264) 3,071 3,295 5,303
Less: Comprehensive income/(loss) attributable to noncontrolling interests (1) 18 4 22
Comprehensive income/(loss) attributable to Pfizer Inc. $ (263) $ 3,053 $ 3,291 $ 5,282
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.